Therefore, the addition of Tdp1 inhibitors to chemotherapeutic cocktails is a promising strategy for increasing the sensitivity of tumor cells to Top1 inhibitors, in particular Tpc, and reducing their overall toxicity to the body due to a lower therapeutic dose. The gene discussed is TDP1; the disease is neoplasm.